Qingdao Vland Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Qingdao Vland Biotech has a total shareholder equity of CN¥1.9B and total debt of CN¥750.7M, which brings its debt-to-equity ratio to 40.4%. Its total assets and total liabilities are CN¥3.0B and CN¥1.2B respectively. Qingdao Vland Biotech's EBIT is CN¥116.7M making its interest coverage ratio 7.7. It has cash and short-term investments of CN¥500.6M.
Key information
40.4%
Debt to equity ratio
CN¥750.67m
Debt
| Interest coverage ratio | 7.7x |
| Cash | CN¥500.55m |
| Equity | CN¥1.86b |
| Total liabilities | CN¥1.17b |
| Total assets | CN¥3.03b |
Recent financial health updates
No updates
Recent updates
Why Investors Shouldn't Be Surprised By Qingdao Vland Biotech INC.'s (SHSE:603739) 28% Share Price Surge
Nov 08
Qingdao Vland Biotech's (SHSE:603739) Anemic Earnings Might Be Worse Than You Think
Nov 04Some Qingdao Vland Biotech INC. (SHSE:603739) Shareholders Look For Exit As Shares Take 27% Pounding
Sep 05Qingdao Vland Biotech INC.'s (SHSE:603739) Popularity With Investors Under Threat As Stock Sinks 26%
Jun 07Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings
May 06Qingdao Vland Biotech INC. (SHSE:603739) Might Not Be As Mispriced As It Looks
Apr 16Financial Position Analysis
Short Term Liabilities: 603739's short term assets (CN¥1.1B) exceed its short term liabilities (CN¥1.0B).
Long Term Liabilities: 603739's short term assets (CN¥1.1B) exceed its long term liabilities (CN¥155.7M).
Debt to Equity History and Analysis
Debt Level: 603739's net debt to equity ratio (13.5%) is considered satisfactory.
Reducing Debt: 603739's debt to equity ratio has increased from 3% to 40.4% over the past 5 years.
Debt Coverage: 603739's debt is well covered by operating cash flow (22.9%).
Interest Coverage: 603739's interest payments on its debt are well covered by EBIT (7.7x coverage).